Eli Lilly (NYSE:LLY) has won Health Canada approval for Omvoh (mirikizumab) in patients with Crohn’s disease, the company said on Tuesday. Omvoh is now indicated for both forms of inflammatory bowel ...

Health technology assessment (HTA) agency NICE has published final draft guidance for IL-23 inhibitor Omvoh (mirikizumab), ...

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

President Donald Trump’s approval ratings remain underwater as he gets mixed reviews on his immigration crackdown, economic handling and foreign policy five months into his second administration ...

President Donald Trump’s approval ratings remain underwater as he gets mixed reviews on his immigration crackdown, economic handling and foreign policy five months into his second administration ...

President Donald Trump’s approval ratings remain underwater as he gets mixed reviews on his immigration crackdown, economic handling and foreign policy five months into his second administration.